Case-Compare Impact Report

Size: px
Start display at page:

Download "Case-Compare Impact Report"

Transcription

1 Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March 4, 20) Available at: Summary Launched online: 07/27/20 Available for credit through: 07/27/202 Healthcare Provider Performance Gaps: Medscape, LLC identified an educational need and a clinical performance gap in the area of assessment and management of asthma and submitted a proposal for the development of a CME activity and metrics reporting. This activity was supported by an independent educational grant from Genentech. Education Delivered: The CME activity was developed for pulmonologists who treat patients with severe asthma. National Jewish Health designated this educational activity for a maximum of 0.5 AMA PRA Category credit(s) TM. Educational Metrics Results: Pulmonologist participants showed improvement ranging from percentage points in practice choices related to the initial assessment and long-term management of patients with severe asthma. Further education is recommended in the areas of disease severity assessment, follow-up, and long-term management. Table of Contents Executive Summary...2 Background Method Main Findings Conclusions Faculty Insights and Recommendations...2 Study Design...3 Metrics Results: Participant Response Data Analysis...4 Qualitative Participant Feedback... 8 Summary of Findings...8 Recommendations...8 Addendum : Data Tables...9 Addendum 2: References for Evidence-Based Activity...3

2 Executive Summary Background With the goal of improving patient care, Medscape, LLC and National Jewish Health identified performance gaps among pulmonologists in adherence to current National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3 (EPR- 3) Guidelines for the Diagnosis and Management of Asthma, which contributes to substantial variation in asthma outcomes. An independent educational grant was awarded to Medscape, LLC and National Jewish Health by Genentech to develop a CME activity and to report metrics on the effects of education. Main Target Audience Pulmonologists Other Target Audiences Allergists, primary care physicians, and all other healthcare professionals who help care for patients with asthma. Method An Internet-based CME activity posted on Medscape was developed for the target audience using a patient case example: a 48-year-old man with severe persistent asthma. It was modeled on the interactive grand rounds approach of testing participant knowledge first and then providing answers and explanations. The success of education was assessed by comparing intra-activity question responses with post-assessment question responses to demonstrate measurable improvements in a patient care scenario. Main Findings For pulmonologists who participated in the CME activity, responses to patient case-based questions demonstrated improvements directly related to the educational learning objectives. Faculty Course Director Rohit Katial, MD Professor of Medicine National Jewish Health and University of Colorado Denver Program Director of Allergy & Immunology Director of Weinberg Clinical Research Unit Director of Allergy & Immunology Clinical Services National Jewish Heath Denver, Colorado Rohit Katial, MD, reviewed the analysis of the metrics within this report. Improvement was shown by: 64% improvement in appropriate assessment of a patient s asthma severity 45% increase in appropriate selection of a patient s initial treatment regimen 30% increase in understanding the role of a follow-up visit after a change in a patient s treatment regimen Conclusions Improved quality of patient care by the pulmonologists who completed the CME activity demonstrates success of education. Improvement was seen in the areas of initial assessment and long-term management of patients with severe asthma. Pulmonologists continue to need additional education in the initial assessment, treatment, and long-term management of patients with asthma. October 8, 20 PAGE 2

3 Study Design Intent Medscape, LLC and National Jewish Health developed the CME activity with expert faculty Rohit Katial, MD, as an Internet-based test-and-teach activity modeled on the interactive grand rounds approach. The activity content addresses healthcare provider performance gaps identified in the needs assessment to meet the educational learning objectives listed to the right. Patient Case Introduction A 48-year-old man who has shortness of breath, wheezing, and chest tightness for several months presents to the clinic. His medical history is notable for gastroesophageal reflux disease, rhinitis, and anxiety. In addition, he had required prednisone bursts in the past year. Analysis Metrics results of participant responses for all intra-activity questions are reported. Paired comparison of intra-activity questions with corresponding post-assessment questions shows the effect of education for 3 questions, noted below. INTRA-ACTIVITY QUESTION CORRESPONDING POST-TEST QUESTION CORRESPONDING LEARNING OBJECTIVE 2 2, 3, 3 2, 3 Learning Objectives Upon completion of this activity, participants will be able to: 2 3 Identify patients who have moderate-to-severe persistent asthma and determine the need for step-up therapy Implement a step-up approach to therapy for patients with uncontrolled asthma based on NAEPP EPR-3 guideline recommendations Outline communication strategies for optimal referral and co-management of patients with severe asthma between primary care providers and specialists October 8, 20 PAGE 3

4 Metrics Results: Participant Response Data Analysis Analysis of target pulmonologist learner responses* to interactive questions are represented, including insight on clinical relevance of the findings to patient care. Complete data for the main target audience and other target audiences are available in Addendum 2. Activity participants not within the main target audience are not represented in the findings of this study. Note that correct answer choices are highlighted in yellow and that percentages have been rounded to the nearest whole number. *Number of learner responses varies by question and is included below the data for each question. How would you characterize the severity of this patient s asthma? Post-test Question. A 48-year-old man comes into the office after experiencing shortness of breath, wheezing, chest tightness, and night awakening for the past several months. His medical history is notable for a diagnosis of anxiety and cold-induced rhinitis. In addition, he has taken prednisone 3 times in the past year. His social history is notable for tobacco use although he does not smoke daily. A pulmonary function test reveals that his forced expiratory volume in second (FEV) is 72% of predicted and his FEV to forced vital capacity ratio is 62%. Finally, he had a 3% improvement in his FEV after use of a bronchodilator. Based on the available information how would you classify the severity of this patient s asthma? 4% Mild intermittent 3% Mild persistent 62% Moderate persistent 2% *Severe persistent 0% Mild intermittent 3% Mild persistent 2% Moderate persistent 85% *Severe persistent n = 278 n = 54 ANALYSIS: Establishment of a patient s asthma disease severity is necessary to determine the initial treatment regimen. Misclassification of asthma severity may result in over- or undertreatment, unnecessary morbidity, or even death. Although nearly 80% of pulmonologists incorrectly assessed the patient s severity in the presented case, significant improvement occurred immediately following participation in the activity. However, additional education is needed to reinforce the education gained on how to properly assess a patient s asthma severity so that learning is maintained long term. EDUCATION EFFECT: Comparing intra-activity and post-assessment scores shows an increase of 64 percentage points in appropriate response to classification of a patient s asthma severity among pulmonologists who participated in the CME activity. October 8, 20 PAGE 4

5 Metrics Results: Participant Response Data Analysis 2 In addition to addressing the patient s smoking and environmental exposures, which of the following treatment regimens would be most appropriate? Post-test Question 2. Based on your assessment of the patient s disease severity, which of the following treatment regimens would be most appropriate? % Short-acting beta-2 agonist as needed 5% Low-dose ICS plus LABA 39% *Medium-dose ICS plus LABA 55% High-dose ICS plus LABA n = 243 0% Short-acting beta-2 agonist as needed 6% Low-dose inhaled corticosteroid plus long-acting beta-agonist 86% *Medium-dose inhaled corticosteroid plus long-acting beta-agonist 8% High-dose inhaled corticosteroid plus long-acting beta-agonist n = 56 ANALYSIS: As demonstrated by this patient case, lack of clinician familiarity with proper assessment of asthma severity and how it guides treatment decisions can result in inappropriate therapy recommendations. Specifically, the patient in this case would have been overtreated by over half of the pulmonologists who took this activity, which would have put him at an increased risk for adverse events. EDUCATION EFFECT: Comparing intra-activity and post-assessment scores shows an increase of 45 percentage points in appropriate response about a patient s initial treatment regimen among the pulmonologists who participated in the CME activity. October 8, 20 PAGE 5

6 Metrics Results: Participant Response Data Analysis 3 How soon after initiation of therapy should this patient be seen for a follow-up visit? Post-test Question 3. How soon after initiating therapy should this patient be seen for a follow-up visit? 28% 2 weeks 67% *2-6 weeks 4% 2-6 months % The next time he is having trouble breathing n = 236 % 2 weeks 97% *2-6 weeks 2% 2-6 months 0% The next time he is having trouble breathing n = 54 ANALYSIS: The NAEPP EPR-3 guidelines recommend a follow-up visit for all patients within 2-6 weeks after initiating a new therapy or regimen. Most pulmonologists were aware that visits should occur within at least 2 weeks of a prior visit. EDUCATION EFFECT: Comparing intra-activity and post-assessment scores shows an increase of 30 percentage points in appropriate response to follow-up care among pulmonologists who participated in the CME activity. October 8, 20 PAGE 6

7 Metrics Results: Participant Response Data Analysis 4 How would you characterize this patient s asthma control? 3% Well controlled 60% Not well controlled 37% *Very poorly controlled n = 23 ANALYSIS: Although the patient in this case stated that he believed that he was doing better, several clinical factors (ie, albuterol use, night awakenings) and his asthma control test score indicated that his asthma was still not under control. In addition, pulmonary function testing revealed that a fairly significant level of obstruction remained even while on medium-dose combination therapy. Cumulatively, these data suggest that the patient s asthma is very poorly controlled and that a change in his regimen is needed to improve control of his asthma. However, only 37% of pulmonologists would classify this patient as having very poorly controlled asthma, which could put patients at risk for undertreatment and poor clinical outcomes. Further education on assessment of asthma control and step-up therapy is needed. 5 The patient s symptoms, lung function, and ACT score show that he has improved. You should: 3% Keep him on a daily dose of oral prednisone (5-0 mg per day) indefinitely 6% Add montelukast 46% *Increase his regimen to a high-dose ICS + LABA 4% Add omalizumab 4% Consider reducing the dose of the ICS 0% Stop the ICS and return to albuterol as needed ANALYSIS: Although a short course of oral prednisone helped the patient in this case obtain control of his asthma, it is likely that he will need to have his controller medication increased at least temporarily to maintain control. Unfortunately, 4% of pulmonologists would have reduced the dose of the inhaled corticosteroid putting the patient back at risk for poorly controlled asthma, an exacerbation of his asthma, and unnecessary morbidity when and if the asthma symptoms return. n = 20 October 8, 20 PAGE 7

8 Qualitative Participant Feedback CME participants were given the opportunity to provide comments on the activity via a free-text form. The following is a representative sampling: This Enjoyed Great was an excellent format with a case-based discussion that incorporated much more than the specific case being discussed. Very nice job! this CME! topic, very well presented. Participants submitted requests for additional educational activities on: Pneumonia Emergent exacerbations of asthma Spirometry interpretation Moderate-to-severe asthma Allergic asthma Summary of Findings For pulmonologists who participated in the CME activity, overall responses to patient case-based questions demonstrate improved quality of patient care related directly to the learning objectives of the activity. Specifically, improved patient care choices were shown by 30%-64% improvement in their knowledge about assessment of disease severity, follow-up, and treatment regimen selection. Success of education is demonstrated by the improved quality of patient care by the pulmonologists who completed the CME activity, specifically in the areas of assessment and initial treatment selection. Recommendations for Future Education On the basis of the CME participants responses to clinical practice questions and the qualitative feedback from faculty, further education is needed for pulmonologists on assessment of asthma severity, initial treatment regimens, and use of step-up therapy. October 8, 20 PAGE 8

9 Addendum : Data Tables How would you characterize the severity of this patient s asthma? (n = 278) (n = 36) (n = 23) Mild intermittent 4% % 2% 2 Mild persistent 3% 7% 9% 3 Moderate persistent 62% 63% 63% 4 *Severe persistent 2% 29% 6% Post-test Question. A 48-year-old man comes into the office after experiencing shortness of breath, wheezing, chest tightness, and night awakening for the past several months. His medical history is notable for a diagnosis of anxiety and cold-induced rhinitis. In addition, he has taken prednisone 3 times in the past year. His social history is notable for tobacco use although he does not smoke daily. A pulmonary function test reveals that his forced expiratory volume in second (FEV) is 72% of predicted and his FEV to forced vital capacity ratio is 62%. Finally, he had a 3% improvement in his FEV after use of a bronchodilator. Based on the available information how would you classify the severity of this patient s asthma? (n = 56) (n = 76) (n = 36) Mild intermittent 0% 0% 0% 2 Mild persistent 3% % 3% 3 Moderate persistent 2% 9% 9% 4 *Severe persistent 85% 90% 78% October 8, 20 PAGE 9

10 Addendum : Data Tables 2 In addition to addressing the patient s smoking and environmental exposures, which of the following treatment regimens would be most appropriate? (n =243) (n = 9) (n = 95) Short-acting beta-2 agonist as needed % 2% % 2 Low-dose ICS plus LABA 5% 4% 3% 3 *Medium-dose ICS plus LABA 39% 50% 48% 4 High-dose ICS plus LABA 55% 44% 38% Post-test Question 2. Based on your assessment of the patient s disease severity, which of the following treatment regimens would be most appropriate? (n = 56) (n = 76) (n = 36) Short-acting beta-2 agonist as needed 0% 0% % 2 Low-dose inhaled corticosteroid plus long-acting beta-agonist 6% 0% 4% 3 *Medium-dose inhaled corticosteroid plus long-acting beta-agonist 86% 84% 84% 4 High-dose inhaled corticosteroid plus long-acting beta-agonist 8% 6% % October 8, 20 PAGE 0

11 Addendum : Data Tables 3 How soon after initiation of therapy should this patient be seen for a follow-up visit? (n =236) (n = 4) (n = 89) 2 weeks 28% 26% 45% 2 *2-6 weeks 67% 70% 50% 3-6 months 4% 4% 4% 4 The next time he s having trouble breathing % 0% % Post-test Question 3. How soon after initiating therapy should this patient be seen for a follow-up visit? (n = 54) (n = 76) (n = 35) 2 weeks % % 3% 2 *2-6 weeks 97% 95% 95% months 2% 3% 2% 4 The next time he is having trouble breathing 0% % 0% October 8, 20 PAGE

12 Addendum : Data Tables 4 How would you characterize this patient s asthma control? (n =23) (n = ) (n = 82) Well controlled 3% 2% 6% 2 Not well controlled 60% 49% 62% 3 *Very poorly controlled 37% 49% 32% 5 The patient s symptoms, lung function, and ACT score show that he has improved. You should: (n =20) (n = 95) (n = 72) Keep him on a daily dose of oral prednisone (5-0 mg per day) indefinitely 3% % 2% 2 Add montelukast 6% 0% 6% 3 *Increase his regimen to a high-dose ICS + LABA 46% 38% 37% 4 Add omalizumab 4% 3% 9% 5 Consider reducing the dose of the ICS 4% 46% 45% 6 Stop the ICS and return to albuterol as needed 0% 2% % October 8, 20 PAGE 2

13 Addendum 2: References for Evidence-Based Activity. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;3: Juniper EF, O Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 999;4: Vollmer WM, Markson LE, O Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med. 999;60: Food and Drug Administration. New safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). Available at: Accessed June 7, 20. October 8, 20 PAGE 3

Outcomes Summary. February 3-6, 2016 Keystone, Colorado

Outcomes Summary. February 3-6, 2016 Keystone, Colorado Outcomes Summary February 3-6, 2016 Keystone, Colorado Executive Summary Activity Details Background: The National Jewish Health Annual The Pulmonary and Allergy Update highlights insights and recent advances

More information

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)

Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review

More information

Optimal Management of Asthma: Use the Right Tools

Optimal Management of Asthma: Use the Right Tools Optimal Management of Asthma: Use the Right Tools Session 1: Optimal Management of Asthma: Use the Right Tools Learning Objectives Develop asthma management plans based on assessment of asthma severity

More information

Learning the Asthma Guidelines by Case Studies

Learning the Asthma Guidelines by Case Studies Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma

More information

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS

TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Recommendation PULMONARY FUNCTION TESTING (SPIROMETRY) Conditional: The Expert Panel that spirometry measurements FEV1,

More information

SCREENING AND PREVENTION

SCREENING AND PREVENTION These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow

More information

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION

Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy HEATHER HOWE, MD UNIVERSITY OF UTAH PULMONARY DIVISION Asthma Management in Pregnancy Effects of asthma on pregnancy outcomes Effects of pregnancy on asthma control Management

More information

Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017

Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 Protocol Title: Adult Asthma Protocol Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 1 Purpose & Objective This protocol provides evidence-based

More information

OUTCOMES SUMMARY REPORT

OUTCOMES SUMMARY REPORT Inhaled Corticosteroids in Asthma: The Balance Between Safety and Efficacy OUTCOMES SUMMARY REPORT Live Educational Activity Series May 5, 2016 December 15, 2016 ME201520772 Grant Number: 1950 MEDA Executive

More information

Office Asthma Care: Practical Elements of Asthma Management. Learning Objectives. Diagnosis

Office Asthma Care: Practical Elements of Asthma Management. Learning Objectives. Diagnosis Office Asthma Care: Practical Elements of Asthma Management Pri-Med West Annual Conference March 29, 2014 Anaheim, CA Sande Okelo, MD, PhD, University of California Los Angeles sokelo@mednet.ucla.edu www.uclahealth.org/pedspulmonology

More information

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy

More information

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network

Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators

More information

Improving the Management of Asthma to Improve Patient Adherence and Outcomes

Improving the Management of Asthma to Improve Patient Adherence and Outcomes Improving the Management of Asthma to Improve Patient Adherence and Outcomes Robert Sussman, MD Atlantic Health System Overlook Medical Center Asthma Remains a Serious Health Risk in the US Every day in

More information

ASTHMA IN THE PEDIATRIC POPULATION

ASTHMA IN THE PEDIATRIC POPULATION ASTHMA IN THE PEDIATRIC POPULATION SEARCH Rotation 2 August 23, 2010 Objectives Define asthma as a chronic disease Discuss the morbidity of asthma in pediatrics Discuss a few things that a health center

More information

Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None

Asthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level

More information

Inhaler Confusion. Today s Speaker Dr. Randall Brown. Director of Asthma Programs 6/7/2016. Dr. Randall Brown March 31, 2016

Inhaler Confusion. Today s Speaker Dr. Randall Brown. Director of Asthma Programs 6/7/2016. Dr. Randall Brown March 31, 2016 + Inhaler Confusion Dr. Randall Brown March 31, 2016 + Today s Speaker Dr. Randall Brown Director of Asthma Programs Center for Managing Chronic Disease University of Michigan 1 ASTHMA ESSENTIALS IN PRIMARY

More information

(Asthma) Diagnosis, monitoring and chronic asthma management

(Asthma) Diagnosis, monitoring and chronic asthma management Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic

More information

Diagnosis, Treatment and Management of Asthma

Diagnosis, Treatment and Management of Asthma Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.

More information

In 2002, it was reported that 72 of 1000

In 2002, it was reported that 72 of 1000 REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and

More information

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma

Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma

More information

Learning and Earning with Gateway Professional Education CME/CEU Webinar Series. Pediatric Asthma: Assessment & Control August 2, :00pm 1:00pm

Learning and Earning with Gateway Professional Education CME/CEU Webinar Series. Pediatric Asthma: Assessment & Control August 2, :00pm 1:00pm Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Pediatric Asthma: Assessment & Control August 2, 2017 12:00pm 1:00pm Allyson S. Larkin, MD Assistant Professor of Pediatrics

More information

Presented by the California Academy of Family Physicians 2013/California Academy of Family Physicians

Presented by the California Academy of Family Physicians 2013/California Academy of Family Physicians Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine

More information

Provider Respiratory Inservice

Provider Respiratory Inservice Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines

More information

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University

More information

Key words: asthma; asthma classification; asthma control; asthma guidelines; asthma severity

Key words: asthma; asthma classification; asthma control; asthma guidelines; asthma severity Supplement DECREASING THE GLOBAL BURDEN OF ASTHMA Classifying Asthma* LeRoy M. Graham, MD, FCCP The most widely known method of asthma classification is the severity classification recommended in the National

More information

CME/CE POSTTEST CME/CE QUESTIONS

CME/CE POSTTEST CME/CE QUESTIONS CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education

More information

#1 cause of school absenteeism in children 13 million missed days annually

#1 cause of school absenteeism in children 13 million missed days annually Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden

More information

The Asthma Guidelines: Diagnosis and Assessment of Asthma

The Asthma Guidelines: Diagnosis and Assessment of Asthma The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma

More information

CHAPTER 5. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma

CHAPTER 5. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma CHAPTER 5 Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma Victor van der Meer, Henk F. van Stel, Moira J. Bakker, Albert C. Roldaan, Willem

More information

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ

Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly

More information

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D.

Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing

More information

Asthma Management for the Athlete

Asthma Management for the Athlete Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric

More information

Clinical Practice Guideline: Asthma

Clinical Practice Guideline: Asthma Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator

More information

HealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA

HealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA The following evidence based guideline was used in developing this clinical care guide: National Institute of Health (NIH National Heart, Lung, and Blood Institute (NHLBI) and American Academy of Allergy,

More information

XOLAIR (omalizumab) Prior Authorization

XOLAIR (omalizumab) Prior Authorization MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists

More information

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org

More information

Asthma for Primary Care: Assessment, Control, and Long-Term Management

Asthma for Primary Care: Assessment, Control, and Long-Term Management Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

Asthma in the Athlete

Asthma in the Athlete Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with

More information

ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009

ASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009 This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN

More information

Clinical Issues Research Implemented April 2010 Asthma Major Recommendations Goals of asthma: - 1) reduction of impairment freedom from symptoms,

Clinical Issues Research Implemented April 2010 Asthma Major Recommendations Goals of asthma: - 1) reduction of impairment freedom from symptoms, Asthma Major Recommendations Goals of : - 1) reduction of impairment freedom from symptoms, such as cough, shortness of breath, wheezing, and disturbed sleep minimal need (< 2 times per week) of short

More information

National Asthma Educator Certification Board Detailed Content Outline

National Asthma Educator Certification Board Detailed Content Outline I. THE ASTHMA CONDITION 9 20 1 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.

More information

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Drug Prior Authorization Guideline NUCALA (mepolizumab) Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1

ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1 ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1 1. Richard Beasley, Bob Hancox, Matire Harwood, Kyle Perrin, Betty Poot, Janine Pilcher, Jim Reid, Api Talemaitoga,

More information

Diagnosis. you have asthma? Get the answers. Your Asthma Basics series: Asthma Basics #1. Diagnosis Triggers Medications Kids

Diagnosis. you have asthma? Get the answers. Your Asthma Basics series: Asthma Basics #1. Diagnosis Triggers Medications Kids Diagnosis Asthma Basics #1 Your Asthma Basics series: 1 2 3 Diagnosis Triggers Medications Kids Supported by unrestricted educational grants from: For more information from the Asthma Society of Canada:

More information

Severity assessment in asthma: An evolving concept

Severity assessment in asthma: An evolving concept Severity assessment in asthma: An evolving concept Mary K. Miller, MS, a Charles Johnson, MBChB, a Dave P. Miller, MS, b Yamo Deniz, MD, a Eugene R. Bleecker, MD, c and Sally E. Wenzel, MD, d for the TENOR

More information

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD

Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Primary Care Medicine: Concepts and Controversies Wed., February 17, 2010 Fiesta Americana Puerto Vallarta, Mexico Update on Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor

More information

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016

Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Get Healthy Stay Healthy

Get Healthy Stay Healthy Asthma Management WHAT IS ASTHMA? Asthma causes swelling and inflammation in the breathing passages that lead to your lungs. When asthma flares up, the airways tighten and become narrower. This keeps the

More information

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma

Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis

More information

Asthma ASTHMA. Current Strategies for Asthma and COPD

Asthma ASTHMA. Current Strategies for Asthma and COPD Current Strategies for Asthma and COPD Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco,

More information

Alberta Childhood Asthma Pathway for Primary Care

Alberta Childhood Asthma Pathway for Primary Care Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and

More information

OUTCOMES SUMMARY REPORT

OUTCOMES SUMMARY REPORT : Current Perspectives in Asthma, Allergy and Pulmonary Practice OUTCOMES SUMMARY REPORT Live Educational Activity Series September 9, 2016 ME201520772 Executive Summary - Activity Details Background:

More information

Evaluation of Asthma Management in Middle EAst North Africa Adult population

Evaluation of Asthma Management in Middle EAst North Africa Adult population STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:

More information

THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP?

THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP? THE NHLBI GUIDELINES: WHERE DO WE STAND AND WHAT IS THE NEW DIRECTION FROM THE NAEPP? Peter S. Creticos, MD ABSTRACT In 1991 and 1997, the National Heart, Lung, and Blood Institute s National Asthma Education

More information

ASTHMA EXACERBATIONS:

ASTHMA EXACERBATIONS: ASTHMA EXACERBATIONS: IDENTIFYING AND ADDRESSING THE ROOT CAUSES MARCH 20, 2017 Speakers Anna Flattau, MD, MSc, MS, Senior Assistant Vice President Chief Clinical Officer OneCity Health Services/NYC Health

More information

The Burden of Asthma and Improving Patient Outcomes

The Burden of Asthma and Improving Patient Outcomes n reports n The Burden of Asthma and Improving Patient Outcomes Aidan A. Long, MD Prevalence and Epidemiology of Asthma In an era of scientific research and breakthroughs, asthma still exacts a significant

More information

Adult asthma management: focus on control

Adult asthma management: focus on control Adult asthma management: focus on control Jennifer W. McCallister, MD Associate Professor Pulmonary, Allergy, Critical Care & Sleep Medicine The Ohio State University Wexner Medical Center Objectives Apply

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

The Appropriate Omalizumab Patient Management of the uncontrolled asthma patient and case examples

The Appropriate Omalizumab Patient Management of the uncontrolled asthma patient and case examples The Appropriate Patient Management of the uncontrolled asthma patient and case examples Jill Karpel, MD, Donald A. Bukstein, MD,* Robert LoNigro, MD Beth Thalheim Asthma Center, North Shore University

More information

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?

Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty

More information

Asthma: diagnosis and monitoring

Asthma: diagnosis and monitoring Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,

More information

Pathology of Asthma Epidemiology

Pathology of Asthma Epidemiology Asthma A Presentation on Asthma Management and Prevention What Is Asthma? A chronic disease of the airways that may cause Wheezing Breathlessness Chest tightness Nighttime or early morning coughing Pathology

More information

Final Outcomes Report 07/23/18

Final Outcomes Report 07/23/18 Final Outcomes Report 07/23/18 36880883 Personalized Medicine in Severe Asthma; Applying Emerging Data and Treatments to Everyday Clinical Practice Educational Objectives 1. Describe key concepts in the

More information

The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma

The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma The methodology behind GINA and EPR-3 medication recommendations: Stepwise treatment in asthma Maureen George PhD RN AE-C FAAN Columbia University mg3656@cumc.columbia.edu Faculty Disclosures Maureen George

More information

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,

More information

Difficult Asthma Assessment: A systematic approach

Difficult Asthma Assessment: A systematic approach Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia

More information

Guideline for the Diagnosis and Management of Chronic Childhood Asthma

Guideline for the Diagnosis and Management of Chronic Childhood Asthma Guideline for the Diagnosis and Management of Chronic Childhood Asthma Guideline developed by Larry A. Simmons, MD, FAAP, Associate Professor of Pediatrics, Department of Pediatrics, UAMS at Arkansas Children

More information

Minimum Competencies for Asthma Care in Schools: School Nurse

Minimum Competencies for Asthma Care in Schools: School Nurse Minimum Competencies for Asthma Care in Schools: School Nurse Area I. Pathophysiology 1. Explain using simple language and appropriate educational aids the following concepts: a. Normal lung anatomy and

More information

USAID Health Care Improvement Project

USAID Health Care Improvement Project IMPROVEMENT OBJECTIVE: Decrease asthma/copd morbidity and mortalityin affected adults and children through improved quality of asthma/copd case-management (ambulatory & hospital) Cross-cutting ambulatory

More information

Public Dissemination

Public Dissemination 1. THE ASTHMA CONDITION 9 18 3 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.

More information

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017

Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Update in Pulmonology Update in Medicine and Primary Care November 11, 2017 Denitza P. Blagev, MD Pulmonary & Critical Care Medicine Director, Schmidt Chest Clinic Director, Lung Cancer Screening Program

More information

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Global Initiative for Asthma (GINA) What s new in GINA 2017? Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome

More information

WEBINAR. Difficult-to-treat and severe asthma: changing the paradigm

WEBINAR. Difficult-to-treat and severe asthma: changing the paradigm WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT

More information

A preliminary assessment of nurses asthma education needs and the effect of a training. programme in an urban tertiary healthcare facility.

A preliminary assessment of nurses asthma education needs and the effect of a training. programme in an urban tertiary healthcare facility. A preliminary assessment of nurses asthma education needs and the effect of a training programme in an urban tertiary healthcare facility O O Adeyeye, Y A Kuyinu, R T Bamisile, and C I Oghama Abstract

More information

Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies

Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric

More information

Outpatient Guideline for the Diagnosis and Management of Asthma

Outpatient Guideline for the Diagnosis and Management of Asthma Outpatient Guideline for the Diagnosis and Management of Asthma Initial Visit Follow-Up Visits See page 2 Asthma Diagnosis See page 3 Classifying Asthma Severity and Initiating Treatment See pages 2 and

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

Global Initiative for Asthma (GINA) What s new in GINA 2016?

Global Initiative for Asthma (GINA) What s new in GINA 2016? Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple

More information

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007

Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy

More information

Project 3dii: Expansion of the Home Environmental Asthma Management Program

Project 3dii: Expansion of the Home Environmental Asthma Management Program 1 Project 3dii: Expansion of the Home Environmental Asthma Management Program Asthma Primary Care Project Participation Opportunity Purpose 2 This Project Participation Opportunity is specifically targeted

More information

Does yours? Most school-age kids with asthma have allergic asthma. Enroll in our support program. Learn about this distinct condition

Does yours? Most school-age kids with asthma have allergic asthma. Enroll in our support program. Learn about this distinct condition Most school-age kids with asthma have allergic asthma. Does yours? Learn about this distinct condition Enroll in our support program for tools, information on financial resources, and more at GetSupportForYou.com

More information

Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis

Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Asthma 2015: Establishing and Maintaining Control

Asthma 2015: Establishing and Maintaining Control Asthma 2015: Establishing and Maintaining Control Webinar for Michigan Center for Clinical Systems Improvement (Mi-CCSI) Karen Meyerson, MSN, APRN, NP-C, AE-C June 16, 2015 Asthma Prevalence Approx. 26

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

NG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80) Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE

More information

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.

ADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma. ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma

More information

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.

Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr

More information

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

Asthma COPD Overlap (ACO)

Asthma COPD Overlap (ACO) Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma

More information

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL

DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis

More information

Nancy Davis, RRT, AE-C

Nancy Davis, RRT, AE-C Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%

More information

COPD COPD. Update on COPD and Asthma

COPD COPD. Update on COPD and Asthma Update on COPD and Asthma Talmadge E. King, Jr., M.D. Krevins Distinguished Professor of Medicine Chair, Department of Medicine University of California San Francisco (UCSF) San Francisco, CA COPD COPD

More information

Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters

Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information